KR20180030254A - 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도 - Google Patents

생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도 Download PDF

Info

Publication number
KR20180030254A
KR20180030254A KR1020187007058A KR20187007058A KR20180030254A KR 20180030254 A KR20180030254 A KR 20180030254A KR 1020187007058 A KR1020187007058 A KR 1020187007058A KR 20187007058 A KR20187007058 A KR 20187007058A KR 20180030254 A KR20180030254 A KR 20180030254A
Authority
KR
South Korea
Prior art keywords
hypogonadism
testosterone
methylene
bisbenzonitrile
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187007058A
Other languages
English (en)
Korean (ko)
Inventor
앤 테일러
로이드 비. 클릭스테인
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180030254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20180030254A publication Critical patent/KR20180030254A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187007058A 2011-09-08 2012-09-06 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도 Ceased KR20180030254A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US61/532,459 2011-09-08
US201261638588P 2012-04-26 2012-04-26
US61/638,588 2012-04-26
PCT/US2012/053844 WO2013036562A1 (en) 2011-09-08 2012-09-06 Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147006170A Division KR20140071358A (ko) 2011-09-08 2012-09-06 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도

Publications (1)

Publication Number Publication Date
KR20180030254A true KR20180030254A (ko) 2018-03-21

Family

ID=46846026

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020147006170A Ceased KR20140071358A (ko) 2011-09-08 2012-09-06 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도
KR1020147006171A Active KR101872561B1 (ko) 2011-09-08 2012-09-06 아로마타제 억제제를 포함하는 제약 조성물
KR1020187007058A Ceased KR20180030254A (ko) 2011-09-08 2012-09-06 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020147006170A Ceased KR20140071358A (ko) 2011-09-08 2012-09-06 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도
KR1020147006171A Active KR101872561B1 (ko) 2011-09-08 2012-09-06 아로마타제 억제제를 포함하는 제약 조성물

Country Status (31)

Country Link
US (4) US9295668B2 (enExample)
EP (2) EP2753313B1 (enExample)
JP (2) JP6051467B2 (enExample)
KR (3) KR20140071358A (enExample)
CN (2) CN103796644B (enExample)
AR (1) AR087790A1 (enExample)
AU (2) AU2012304693B2 (enExample)
BR (2) BR112014005434B1 (enExample)
CA (2) CA2845929C (enExample)
CL (1) CL2014000552A1 (enExample)
CY (2) CY1118461T1 (enExample)
DK (2) DK2753313T3 (enExample)
ES (2) ES2613666T3 (enExample)
HR (2) HRP20170003T1 (enExample)
HU (2) HUE031478T2 (enExample)
IL (1) IL231234A (enExample)
IN (1) IN2014DN01619A (enExample)
LT (2) LT2753313T (enExample)
MX (2) MX343902B (enExample)
PE (1) PE20141584A1 (enExample)
PH (1) PH12014500435A1 (enExample)
PL (2) PL2753313T3 (enExample)
PT (2) PT2753312T (enExample)
RU (2) RU2617510C2 (enExample)
SG (2) SG10201607503WA (enExample)
SI (2) SI2753313T1 (enExample)
TN (1) TN2014000059A1 (enExample)
TW (1) TW201316987A (enExample)
UY (1) UY34315A (enExample)
WO (2) WO2013036563A1 (enExample)
ZA (1) ZA201401040B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140071358A (ko) * 2011-09-08 2014-06-11 노파르티스 아게 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도
WO2015148549A1 (en) * 2014-03-26 2015-10-01 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
SG11201610227TA (en) * 2014-07-07 2017-01-27 Novartis Ag Pharmaceutical dosage forms
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
WO2018165145A1 (en) * 2017-03-08 2018-09-13 Ariad Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490816A2 (de) * 1990-12-12 1992-06-17 Ciba-Geigy Ag Fluorverbindungen
WO2003082254A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
KR20140058619A (ko) * 2011-09-08 2014-05-14 노파르티스 아게 아로마타제 억제제를 포함하는 제약 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
PL366554A1 (en) 2001-04-17 2005-02-07 Ares Trading S.A. Aromatase inhibition to enhance assisted reproduction
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
WO2006114702A2 (en) 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN102335269B (zh) * 2007-11-21 2013-06-19 客乐谐制药株式会社 芳香酶抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490816A2 (de) * 1990-12-12 1992-06-17 Ciba-Geigy Ag Fluorverbindungen
WO2003082254A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
KR20140058619A (ko) * 2011-09-08 2014-05-14 노파르티스 아게 아로마타제 억제제를 포함하는 제약 조성물

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DIABETES, OBESITY AND METABOLISM, vol . 7 , no. 3 , pages 211-215 (2005-05-01) *
European Journal of Endocrunology 158, 741-747(2008) *
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol . 61 , no. 3-6, pages 157-166(1997. 04.) *
Steroids 63:414-420(1998) 1부. *
STEROIDS vol . 63 , no. 7-8, pages 414-420 (1998-07-08) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment

Also Published As

Publication number Publication date
CY1118461T1 (el) 2017-07-12
BR112014004879A2 (pt) 2017-03-14
WO2013036562A1 (en) 2013-03-14
CN103781476A (zh) 2014-05-07
AR087790A1 (es) 2014-04-16
AU2012304693A1 (en) 2014-03-13
PH12014500435A1 (en) 2019-03-22
US9295668B2 (en) 2016-03-29
EP2753312B1 (en) 2016-12-14
DK2753312T3 (da) 2017-02-13
RU2628808C2 (ru) 2017-08-22
SI2753312T1 (sl) 2017-10-30
CN103796644B (zh) 2017-05-03
JP6051467B2 (ja) 2016-12-27
HRP20170003T1 (hr) 2017-03-10
JP6280501B2 (ja) 2018-02-14
IL231234A (en) 2016-12-29
RU2014113575A (ru) 2015-10-20
PL2753312T3 (pl) 2017-06-30
TN2014000059A1 (en) 2015-07-01
US9370505B2 (en) 2016-06-21
MX2014002773A (es) 2014-06-05
LT2753313T (lt) 2017-02-10
EP2753313A1 (en) 2014-07-16
EP2753313B1 (en) 2016-12-14
WO2013036563A1 (en) 2013-03-14
JP2014528932A (ja) 2014-10-30
PT2753312T (pt) 2017-02-03
DK2753313T3 (en) 2017-02-13
US20160243084A1 (en) 2016-08-25
MX343902B (es) 2016-11-28
EP2753312A1 (en) 2014-07-16
BR112014005434A2 (pt) 2017-04-04
PE20141584A1 (es) 2014-11-13
AU2012304694B2 (en) 2016-04-07
MX2014002780A (es) 2014-06-05
ES2613667T3 (es) 2017-05-25
HUE031435T2 (en) 2017-07-28
CA2846884C (en) 2019-04-09
NZ621476A (en) 2016-02-26
CY1118499T1 (el) 2017-07-12
CN103796644A (zh) 2014-05-14
PL2753313T3 (pl) 2017-07-31
AU2012304694A1 (en) 2014-03-20
CA2845929C (en) 2018-06-19
TW201316987A (zh) 2013-05-01
SG10201607503WA (en) 2016-10-28
ZA201401040B (en) 2015-12-23
CL2014000552A1 (es) 2014-09-12
US10064844B2 (en) 2018-09-04
MX360315B (es) 2018-10-29
CA2845929A1 (en) 2013-03-14
LT2753312T (lt) 2017-01-25
HUE031478T2 (hu) 2017-07-28
KR20140058619A (ko) 2014-05-14
IN2014DN01619A (enExample) 2015-05-15
ES2613666T3 (es) 2017-05-25
RU2014113334A (ru) 2015-10-20
UY34315A (es) 2013-04-30
RU2617510C2 (ru) 2017-04-25
PT2753313T (pt) 2017-02-02
US20140309267A1 (en) 2014-10-16
HRP20170002T1 (hr) 2017-02-24
US20140213622A1 (en) 2014-07-31
JP2014526465A (ja) 2014-10-06
KR101872561B1 (ko) 2018-06-28
AU2012304693B2 (en) 2016-03-31
US20160346257A1 (en) 2016-12-01
SI2753313T1 (sl) 2017-04-26
BR112014005434B1 (pt) 2021-01-05
US9750724B2 (en) 2017-09-05
CA2846884A1 (en) 2013-03-14
IL231234A0 (en) 2014-04-30
KR20140071358A (ko) 2014-06-11
BR112014004879B1 (pt) 2020-01-28
CN103781476B (zh) 2016-12-07
SG2014012132A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
US9750724B2 (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
JP2001513082A (ja) ヒト成長ホルモンとコルチゾール合成阻害剤とを組み合わせて含む代謝症候群の処置用製剤
CZ382997A3 (cs) Použití sloučenin k přípravě farmaceutického prostředku pro minimalizaci účinku ztráty kostní hmoty a farmaceutický prostředek s obsahem těchto sloučenin
HK1196256A (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
HK1196256B (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
US20200179308A1 (en) Use of isohumulones and derivatives thereof to treat polycystic ovary syndrome
NZ621476B2 (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
JP2019524846A (ja) 子宮内膜症の治療のための投与レジメン
US20150164788A1 (en) Use of vaginal insulin sensitizing agents
RU2649757C1 (ru) Пероральная форма бигормональной композиции для регуляции половой охоты у мелких домашних животных (варианты)
WO2018011015A1 (en) Low-dosed oral dosage forms for treatment of diseases
DK2399583T3 (en) The use of insulin-sensitizing agents administered vaginally
CN119894515A (zh) 用黄体生成素受体激动剂治疗肥胖症的方法
MXPA97001532A (en) Procedure to increase testoster levels
HK1097752A (en) Methods for preventing antipsychotic-induced weight gain

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180312

Application number text: 1020147006170

Filing date: 20140307

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180411

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180611

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190909

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180611

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190909

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190711

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191114

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200218

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200110

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20191114

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191106

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190909

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190711

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180611

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20200318

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20200218

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20190909

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20210513

Appeal identifier: 2020101000804

Request date: 20200318

J301 Trial decision

Free format text: TRIAL NUMBER: 2020101000804; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20200318

Effective date: 20210513

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20210513

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20200318

Decision date: 20210513

Appeal identifier: 2020101000804